×

Method of treating cancer with IL-10 and antibodies that induce ADCC

  • US 10,618,970 B2
  • Filed: 02/01/2016
  • Issued: 04/14/2020
  • Est. Priority Date: 02/03/2015
  • Status: Active Grant
First Claim
Patent Images

1. A method of treating cancer in a human subject, comprising administering to the subject:

  • a) an antibody capable of inducing antibody-dependent cell-mediated cytotoxicity (ADCC), wherein the antibody is selected from the group consisting of cetuximab, trastuzumab, zalutumumab, matuzumab, rituximab, trastuzumab, ipilumumab, and nimotuzumab, andb) a therapeutically effective amount of an IL-10 agent, wherein the IL-10-agent is administered in an amount sufficient to maintain a mean IL-10 serum trough concentration of at least 1 ng/ml over a period of time of at least 1 week, wherein the mean IL-10 serum trough concentration is maintained for at least 90% of the period of time.

View all claims
  • 2 Assignments
Timeline View
Assignment View
    ×
    ×